GSK announces intention to sell about 385M shares in Haleon

GSK plc (GSK) announced that it intends to sell approximately 385M ordinary shares in Haleon (HLN), equivalent to approximately 4.2% of Haleon’s issued share capital and representing GSK’s entire shareholding in Haleon. Following the successful demerger and premium listing of Haleon plc as announced on July 18, 2022, GSK initially retained a 12.94% stake in Haleon. As a result of the disposals announced in May 2023, October 2023 and January 2024, GSK has since sold a total of 810M ordinary shares in Haleon, reducing its stake in Haleon to approximately 4.2%. “The disposal announced today will be conducted through a placing of ordinary shares in Haleon to institutional investors. The offer price will be determined by means of an accelerated bookbuild offering process which is to start immediately. A further announcement will be made following completion of the bookbuild and pricing of the Offering. GSK has entered into a secondary block trade agreement with BofA Securities and Goldman Sachs International under which BofA and Goldman Sachs have been appointed to act as the Joint Global Coordinators of the Offering,” GSK stated.